This post was originally published on this site
Merck&Co announced earnings per share of $1.74 on revenue of $12.55B. Analysts polled by Investing.com anticipated EPS of $1.44 on revenue of $12.19B.
Merck&Co shares are down 13% from the beginning of the year, still down 14.90% from its 52 week high of $92.64 set on December 20, 2019. They are under-performing the Dow Jones which is down 2.99% from the start of the year.
Merck&Co’s report follows an earnings beat by J&J on October 13, who reported EPS of $2.2 on revenue of $21.08B, compared to forecasts EPS of $1.98 on revenue of $20.2B.
Pfizer had beat expectations on Tuesday with third quarter EPS of $0.72 on revenue of $12.13B, compared to forecast for EPS of $0.69 on revenue of $12.31B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
